Regen BioPharma (RGBP) Debt to Equity (2016 - 2024)
Regen BioPharma (RGBP) has disclosed Debt to Equity for 9 consecutive years, with -$0.16 as the latest value for Q2 2024.
- On a quarterly basis, Debt to Equity fell 290.09% to -$0.16 in Q2 2024 year-over-year; TTM through Jun 2024 was -$0.16, a 290.09% decrease, with the full-year FY2023 number at -$0.07, up 25.46% from a year prior.
- Debt to Equity was -$0.16 for Q2 2024 at Regen BioPharma, down from -$0.11 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.18 in Q4 2020 to a low of -$0.18 in Q4 2023.
- A 5-year average of -$0.04 and a median of -$0.03 in 2021 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: surged 3608.03% in 2020, then plummeted 11996.88% in 2022.
- Regen BioPharma's Debt to Equity stood at $0.18 in 2020, then crashed by 100.18% to -$0.0 in 2021, then tumbled by 11996.88% to -$0.04 in 2022, then tumbled by 381.58% to -$0.18 in 2023, then rose by 14.76% to -$0.16 in 2024.
- Per Business Quant, the three most recent readings for RGBP's Debt to Equity are -$0.16 (Q2 2024), -$0.11 (Q1 2024), and -$0.18 (Q4 2023).